Neurocore investigated the marketing of Michigan-based “brain training” company Neurocore and determined that the company claimed its neurofeedback sessions could treat numerous medical conditions, including ADHD, anxiety, autism, depression, migraines, memory loss and insomnia, without competent and reliable scientific evidence to support such treatment claims.


  • Filed complaint with the FTC regarding unsubstantiated claims
  • Filed complaint with the FDA regarding use of unapproved medical device


April 22

The FTC informs the NARB that it is closing out its investigation without enforcement action.

January 13

The NARB refers advertising claims made by Neurocore to the FTC for review after the NARB concludes that the company did not comply with NARB’s recommendations.

November 12

After its own investigation, files complaint letters with the FTC and FDA against Neurocore urging both agencies to take appropriate enforcement action.

June 4

The National Advertising Review Board (NARB) panel affirms NAD’s decision.

August 9

The National Advertising Division (NAD) recommends that Neurocore discontinue certain advertising claims for the company’s “Brain Training Centers,” including claims related to Attention Deficit/Hyperactivity Disorder (ADHD), autism, migraines, memory issues, sleep disorders and stress.


The Latest